Q
QuantAbundanciaAbundance, Quantified.

News

High-signal headlines only - macro events, earnings, M&A, regulatory. Listicles and analyst clickbait filtered out by default. Refreshed hourly.

24,221 signal articles · 220 in last 24h · 115,008 total before filter · latest 2h ago
220last 24h
1830last 7d
302● bullish (7d)
167● bearish (7d)
205publishers
AllMacro322Earnings879M&A103Regulatory23Product17Analyst23
✕ clear all filtersSentiment:bullishneutralbearishshow all (incl. clickbait)
RE/MAX (RMAX): Buy, Sell, or Hold Post Q1 Earnings?
StockStory30d agoneutral
RE/MAX (RMAX): Buy, Sell, or Hold Post Q1 Earnings?

Over the past six months, RE/MAX has been a great trade, beating the S&P 500 by 29.9%. Its stock price has climbed to $11.26, representing a healthy 38.2% increase. This run-up might have investors contemplating their next move.

The PNC Financial Services Group Q2 Earnings Call Highlights
MarketBeat30d agoneutral
The PNC Financial Services Group Q2 Earnings Call Highlights

The PNC Financial Services Group (NYSE:PNC) reported what Chairman and CEO Bill Demchak called an “impressive” second quarter, with management pointing to broad-based business momentum, stronger fee income, continued commercial loan growth and stable credit quality. PNC generated second-quarter net

Aehr Test Systems surge on earnings beat, strong guidance
Proactive30d agobullish
Aehr Test Systems surge on earnings beat, strong guidance

Aehr Test Systems (NASDAQ:AEHR) shares jumped 30% after the semiconductor test and burn-in equipment provider reported fiscal fourth-quarter results that exceeded Wall Street expectations and provided a stronger-than-anticipated revenue outlook for fiscal 2027. The company posted adjusted...

Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance
Proactive30d agobullish
Johnson & Johnson beats Q2 estimates, raises full-year 2026 guidance

Johnson & Johnson (NYSE:JNJ) reported better-than-expected second quarter results and raised its full-year 2026 outlook, as strong pharmaceutical sales helped offset headwinds from products facing patent competition. The healthcare company posted adjusted earnings per share of $2.90 for...

Morgan Stanley Q2 Earnings Call Highlights
MarketBeat30d agoneutral
Morgan Stanley Q2 Earnings Call Highlights

Morgan Stanley (NYSE:MS) reported record second-quarter 2026 results, with executives citing strong client activity across institutional securities, wealth management and investment management, as well as continued benefits from the firm’s integrated business model. Chairman and Chief Executive Off

Johnson & Johnson Q2 Earnings Call Highlights
MarketBeat30d agoneutral
Johnson & Johnson Q2 Earnings Call Highlights

Johnson & Johnson (NYSE:JNJ) raised its full-year 2026 outlook after reporting second-quarter sales growth that management said was supported by strength in Innovative Medicine, new product launches and a broad portfolio that helped offset continued pressure from STELARA biosimilar competition.